Nurix Therapeutics, Inc. NRIX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s EPS (diluted)?
- Nurix Therapeutics, Inc. (NRIX) reported EPS (diluted) of -$0.79 in Q4 2025.
- How has Nurix Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Nurix Therapeutics, Inc.'s EPS (diluted) decreased by 17.9% year-over-year, from -$0.67 to -$0.79.
- What is the long-term trend for Nurix Therapeutics, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Nurix Therapeutics, Inc.'s EPS (diluted) has grown at a 2.8% compound annual growth rate (CAGR), from -$2.73 to -$3.05.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.